First Citizens Bank & Trust Co. Makes New $1.39 Million Investment in IQVIA Holdings Inc. $IQV

Key Points

• First Citizens Bank acquired 5,160 IQVIA shares worth approximately $1.39 million, while other major institutions also increased or initiated positions. Institutional investors and hedge funds collectively own 89.62% of IQVIA.
• IQVIA reported quarterly EPS of $3.15, beating estimates of $3.03, while revenue rose 8.7% year over year to $4.37 billion. The company issued fiscal 2026 EPS guidance of $12.80–$13.00.
• Analysts maintain a generally positive outlook, with IQVIA holding a “Moderate Buy” consensus rating and an average price target of $276.00; however, insiders sold $3.80 million of stock during the latest quarter.

First Citizens Bank & Trust Co. acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,160 shares of the medical research company's stock, valued at approximately $1,387,000.

Several other institutional investors have also made changes to their positions in IQV. BlackRock Inc. acquired a new position in IQVIA in the second quarter worth about $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in IQVIA by 9.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company's stock valued at $315,772,000 after purchasing an additional 134,997 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in IQVIA by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company's stock valued at $282,657,000 after purchasing an additional 66,643 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of IQVIA in the 2nd quarter valued at approximately $240,911,000. Finally, Bank of America Corp DE bought a new stake in shares of IQVIA in the 2nd quarter valued at approximately $235,551,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other news, insider Bhavik Patel sold 1,855 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James G. Berkshire sold 2,668 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company's stock, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is owned by company insiders.

IQVIA Stock Performance

NYSE IQV opened at $270.80 on Friday. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $277.40. The company has a 50 day moving average of $260.18 and a 200-day moving average of $212.46. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market cap of $44.57 billion, a price-to-earnings ratio of 23.06, a PEG ratio of 2.27 and a beta of 1.17.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. IQVIA's revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 11.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent analyst reports. Wall Street Zen raised IQVIA from a "hold" rating to a "buy" rating in a research note on Saturday, September 12th. Weiss Ratings upgraded IQVIA from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, September 24th. Royal Bank Of Canada lifted their price objective on IQVIA from $247.00 to $319.00 and gave the company an "outperform" rating in a report on Tuesday, September 29th. JPMorgan Chase & Co. boosted their target price on shares of IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $276.00.

IQVIA Company Profile

IQVIA Holdings Inc NYSE: IQV is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA's offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.